Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical Outcomes and Biomarker Profiles of Elderly Pretreated NSCLC Patients from the BATTLE Trial

11 Oct 2012

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer Immunotherapy and Biomarkers
Share to Lung Cancer Diagnosis and Treatment
Share to Lung Cancer Treatments and Mutations

Source

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Identifiers

PMID: 23059780
DOI: 10.1097/jto.0b013e31826910ff

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical Outcomes and Biomarker Profiles of Elderly Pretreated NSCLC Patients from the BATTLE TrialPMID 23059780Read ↗

Refining the treatment of NSCLC according to histological and molecular subtypesSemantic proximity Read ↗

EGFR monoclonal antibody biomarkers in advanced NSCLC: from translational research to clinical implementation.Semantic proximity Read ↗

Impact of Patient Characteristics, Prior Therapy, and Sample Type on Tumor Cell Programmed Cell Death Ligand 1 Expression in Patients with Advanced NSCLC Screened for the ATLANTIC StudySemantic proximity Read ↗

Concomitant Actionable Mutations and Overall Survival (OS) in Egfr-Mutant Non-Small-Cell Lung Cancer (NSCLC) Patients (P) Included in The Eurtac Trial: EGFR L858R, EGFR T790M, TP53 R273H and EML4-ALK (V3)Semantic proximity Read ↗

Treatment outcomes in elderly with advanced-stage non-small cell lung cancer.Semantic proximity Read ↗

Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.Semantic proximity Read ↗

Recent advances in targeted advanced lung cancer therapy in the elderly.Semantic proximity Read ↗

Current readings: Window-of-opportunity trials for thoracic malignancies.Semantic proximity Read ↗

Population-based differences in treatment outcome following anticancer drug therapies.Semantic proximity Read ↗

First-line pyrotinib in advanced HER2-mutant non-small-cell lung cancer: a patient-centric phase 2 trialSemantic proximity Read ↗

Clinical and biomarker outcomes of the phase II vandetanib study from the BATTLE trial.Semantic proximity Read ↗

Clinical features and outcomes of first-line EGFR-TKI treatment in younger and older patients with EGFR-mutated NSCLC.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.